Clarithromycin prevents human respiratory syncytial virus-induced airway epithelial responses by modulating activation of interferon regulatory factor-3

Pharmacological Research

Volumn 111, Issue , 2016, Pages 804-814

  Yamamoto, Keisuke ^a   Yamamoto, Soh ^a   Ogasawara, Noriko ^a   Takano, Kenichi ^a   Shiraishi, Tsukasa ^a   Sato, Toyotaka ^a   Miyata, Ryo ^a   Kakuki, Takuya ^a   Kamekura, Ryuta ^a   Kojima, Takashi ^a   Tsutsumi, Hiroyuki ^a   Himi, Tetsuo ^a   Yokota, Shin ichi ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Airway epithelial cells; Innate immunity; Interferon; IRF 3; Macrolide

Indexed keywords

BETA INTERFERON; CLARITHROMYCIN; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 8; POLYINOSINIC POLYCYTIDYLIC ACID; RANTES; TOLL LIKE RECEPTOR AGONIST; AUTACOID; IMMUNOLOGIC FACTOR; INTERFERON; IRF3 PROTEIN, HUMAN; TLR3 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 3;

A549 CELL LINE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BEAS 2B CELL LINE; CELL LINE; CELL NUCLEUS; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIMERIZATION; DRUG EFFECT; EPITHELIUM CELL; GENE ACTIVITY; HUMAN; HUMAN CELL; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOMODULATION; INNATE IMMUNITY; INTRACELLULAR TRANSPORT; LUNG ALVEOLUS EPITHELIUM; NONHUMAN; NOSE MUCOSA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN TRANSPORT; RESPIRATORY EPITHELIUM; RESPIRATORY SYNCYTIAL VIRUS INFECTION; TISSUE REACTION; TRANSCRIPTION INITIATION; A-549 CELL LINE; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; LUNG; METABOLISM; NUCLEOCYTOPLASMIC TRANSPORT; PATHOGENICITY; PROTEIN MULTIMERIZATION; SIGNAL TRANSDUCTION; VIROLOGY;

A549 CELLS; ACTIVE TRANSPORT, CELL NUCLEUS; CLARITHROMYCIN; EPITHELIAL CELLS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; INFLAMMATION MEDIATORS; INTERFERON REGULATORY FACTOR-3; INTERFERONS; LUNG; PROTEIN MULTIMERIZATION; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 3; TRANSFECTION;

EID: 84980356997     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.07.033     Document Type: Article

References (77)

1. [1] Kanoh, S., Rubin, B.K., Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin. Microbiol. Rev. 23:3 (2010), 590–615.
2. [2] Park, J.Y., Kim, H.Y., Lee, J.Y., Kim, K.H., Jang, M.K., Lee, J.H., Yoo, J.Y., Han, D.S., Hahm, J.S., Macrolide-affected Toll-like receptor 4 expression from Helicobacter pylori-infected monocytes does not modify interleukin-8 production. FEMS Immunol. Med. Microbiol. 44:2 (2005), 171–176.
3. [3] Shinkai, M., Foster, G.H., Rubin, B.K., Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 290:1 (2006), L75–85.
4. [4] Shinkai, M., Lopez-Boado, Y.S., Rubin, B.K., Clarithromycin has an immunomodulatory effect on ERK-mediated inflammation induced by Pseudomonas aeruginosa flagellin. J. Antimicrob. Chemother. 59:6 (2007), 1096–1101.
5. [5] Asada, M., Yoshida, M., Suzuki, T., Hatachi, Y., Sasaki, T., Yasuda, H., Nakayama, K., Nishimura, H., Nagatomi, R., Kubo, H., Yamaya, M., Macrolide antibiotics inhibit respiratory syncytial virus infection in human airway epithelial cells. Antiviral Res. 83:2 (2009), 191–200.
6. [6] Miyanohara, T., Ushikai, M., Matsune, S., Ueno, K., Katahira, S., Kurono, Y., Effects of clarithromycin on cultured human nasal epithelial cells and fibroblasts. Laryngoscope 110:1 (2000), 126–131.
7. [7] Ichiyama, T., Nishikawa, M., Yoshitomi, T., Hasegawa, S., Matsubara, T., Hayashi, T., Furukawa, S., Clarithromycin inhibits NF-κB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells. Antimicrob. Agents Chemother. 45:1 (2001), 44–47.
8. [8] Kikuchi, T., Hagiwara, K., Honda, Y., Gomi, K., Kobayashi, T., Takahashi, H., Tokue, Y., Watanabe, A., Nukiwa, T., Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-κB transcription factors. J. Antimicrob. Chemother. 49:5 (2002), 745–755.
9. [9] Uriarte, S.M., Molestina, R.E., Miller, R.D., Bernabo, J., Farinati, A., Eiguchi, K., Ramirez, J.A., Summersgill, J.T., Effect of macrolide antibiotics on human endothelial cells activated by Chlamydia pneumoniae infection and tumor necrosis factor-α. J. Infect. Dis. 185:11 (2002), 1631–1636.
10. [10] Takaki, M., Ushikai, M., Deguchi, K., Nishimoto, K., Matsune, S., Kurono, Y., The role of nuclear factor-κB in interleukin-8 expression by human adenoidal fibroblasts. Laryngoscope 113:8 (2003), 1378–1385.
11. [11] Cameron, E.J., McSharry, C., Chaudhuri, R., Farrow, S., Thomson, N.C., Long-term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments. Clin. Exp. Allergy 42:9 (2012), 1302–1312.
12. [12] Friedlander, A.L., Albert, R.K., Chronic macrolide therapy in inflammatory airways diseases. Chest 138:5 (2010), 1202–1212.
13. [13] Simpson, J.L., Powell, H., Boyle, M.J., Scott, R.J., Gibson, P.G., Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am. J. Respir. Crit. Care Med. 177:2 (2008), 148–155.
14. [14] Barnes, P.J., Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes. J. Allergy Clin. Immunol. 136:3 (2015), 531–545.
15. [15] Tahan, F., Ozcan, A., Koc, N., Clarithromycin in the treatment of RSV bronchiolitis: a double-blind, randomised, placebo-controlled trial. Eur. Respir. J. 29:1 (2007), 91–97.
16. [16] Miyashita, N., Kawai, Y., Kato, T., Tanaka, T., Akaike, H., Teranishi, H., Nakano, T., Ouchi, K., Okimoto, N., Macrolide therapy for prevention of exacerbation in individuals with diffuse aspiration bronchiolitis. J. Am. Geriatr. Soc. 64:3 (2016), 665–666.
17. [17] Restrepo, M.I., Sole-Violan, J., Martin-Loeches, I., Macrolide therapy of pneumonia: is it necessary, and how does it help?. Curr. Opin. Infect. Dis. 29:2 (2016), 212–217.
18. [18] Southern, K.W., Barker, P.M., Solis-Moya, A., Patel, L., Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst. Rev., 11, 2012, CD002203.
19. [19] Kneyber, M.C., Kimpen, J.L., Antibiotics in RSV bronchiolitis: still no evidence of effect. Eur. Respir. J., 29(6), 2007, 1285.
20. [20] Farley, R., Spurling, G.K., Eriksson, L., Del Mar, C.B., Antibiotics for bronchiolitis in children under two years of age. Cochrane Database Syst. Rev., 10, 2014, CD005189.
21. [21] Silva Filho, L.V., Pinto, L.A., Stein, R.T., Use of macrolides in lung diseases: recent literature controversies. J. Pediatr. (Rio. J) 91:6 Suppl. 1 (2015), S52–S60.
22. [22] Yokota, S., Okabayashi, T., Hirakawa, S., Tsutsumi, H., Himi, T., Fujii, N., Clarithromycin suppresses human respiratory syncytial virus infection-induced Streptococcus pneumoniae adhesion and cytokine production in a pulmonary epithelial cell line. Mediators Inflamm., 2012, 2012, 528568.
23. [23] Yamaya, M., Shinya, K., Hatachi, Y., Kubo, H., Asada, M., Yasuda, H., Nishimura, H., Nagatomi, R., Clarithromycin inhibits type a seasonal influenza virus infection in human airway epithelial cells. J. Pharmacol. Exp. Ther. 333:1 (2010), 81–90.
24. [24] Whitsett, J.A., Alenghat, T., Respiratory epithelial cells orchestrate pulmonary innate immunity. Nat. Immunol. 16:1 (2015), 27–35.
25. [25] Schleimer, R.P., Kato, A., Kern, R., Kuperman, D., Avila, P.C., Epithelium: at the interface of innate and adaptive immune responses. J. Allergy Clin. Immunol. 120:6 (2007), 1279–1284.
26. [26] Ohkuni, T., Kojima, T., Ogasawara, N., Masaki, T., Fuchimoto, J., Kamekura, R., Koizumi, J., Ichimiya, S., Murata, M., Tanaka, S., Himi, T., Sawada, N., Poly(I:C) reduces expression of JAM-A and induces secretion of IL-8 and TNF-α via distinct NF-κB pathways in human nasal epithelial cells. Toxicol. Appl. Pharmacol. 250:1 (2011), 29–38.
27. [27] Ogasawara, N., Kojima, T., Go, M., Takano, K., Kamekura, R., Ohkuni, T., Koizumi, J., Masaki, T., Fuchimoto, J., Obata, K., Kurose, M., Shintani, T., Sawada, N., Himi, T., Epithelial barrier and antigen uptake in lymphoepithelium of human adenoids. Acta Otolaryngol. 131:2 (2011), 116–123.
28. [28] Perales-Linares, R., Navas-Martin, S., Toll-like receptor 3 in viral pathogenesis: friend or foe?. Immunology 140:2 (2013), 153–167.
29. [29] Collins, P.L., Melero, J.A., Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res. 162:1–2 (2011), 80–99.
30. [30] Moore, M.L., Stokes, K.L., Hartert, T.V., The impact of viral genotype on pathogenesis and disease severity: respiratory syncytial virus and human rhinoviruses. Curr. Opin. Immunol. 25:6 (2013), 761–768.
31. [31] Kawai, T., Akira, S., Toll-like receptor and RIG-I-like receptor signaling. Ann. N. Y. Acad. Sci. 1143 (2008), 1–20.
32. [32] Murawski, M.R., Bowen, G.N., Cerny, A.M., Anderson, L.J., Haynes, L.M., Tripp, R.A., Kurt-Jones, E.A., Finberg, R.W., Respiratory syncytial virus activates innate immunity through Toll-like receptor 2. J. Virol. 83:3 (2009), 1492–1500.
33. [33] Kell, A.M., Gale, M. Jr., RIG-I in RNA virus recognition. Virology 409–480 (2015), 110–121.
34. [34] Seth, R.B., Sun, L., Ea, C.K., Chen, Z.J., Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-κB and IRF 3. Cell 122:5 (2005), 669–682.
35. [35] Okabayashi, T., Kojima, T., Masaki, T., Yokota, S., Imaizumi, T., Tsutsumi, H., Himi, T., Fujii, N., Sawada, N., Type-III interferon, not type-I, is the predominant interferon induced by respiratory viruses in nasal epithelial cells. Virus Res. 160:1–2 (2011), 360–366.
36. [36] Lopušná, K., Režuchová, I., Betáková, T., Skovranová, L., Tomašková, J., Lukáčiková, L., Kabát, P., Interferons lambda, new cytokines with antiviral activity. Acta Virol. 57:2 (2013), 171–179.
37. [37] Kotenko, S.V., IFN-λs. Curr. Opin. Immunol. 23:5 (2011), 583–590.
38. [38] Donnelly, R.P., Kotenko, S.V., Interferon-lambda: a new addition to an old family. J. Interferon Cytokine Res. 30:8 (2010), 555–564.
39. [39] Takahasi, K., Horiuchi, M., Fujii, K., Nakamura, S., Noda, N.N., Yoneyama, M., Fujita, T., Inagaki, F., Ser386 phosphorylation of transcription factor IRF-3 induces dimerization and association with CBP/p300 without overall conformational change. Genes Cells 15:8 (2010), 901–910.
40. [40] Masaki, T., Kojima, T., Okabayashi, T., Ogasawara, N., Ohkuni, T., Obata, K., Takasawa, A., Murata, M., Tanaka, S., Hirakawa, S., Fuchimoto, J., Ninomiya, T., Fujii, N., Tsutsumi, H., Himi, T., Sawada, N., A nuclear factor-κB signaling pathway via protein kinase C δ regulates replication of respiratory syncytial virus in polarized normal human nasal epithelial cells. Mol. Biol. Cell 22:13 (2011), 2144–2156.
41. [41] Takahasi, K., Suzuki, N.N., Horiuchi, M., Mori, M., Suhara, W., Okabe, Y., Fukuhara, Y., Terasawa, H., Akira, S., Fujita, T., Inagaki, F., X-ray crystal structure of IRF-3 and its functional implications. Nat. Struct. Biol. 10:11 (2003), 922–927.
42. [42] Yoneyama, M., Suhara, W., Fujita, T., Control of IRF-3 activation by phosphorylation. J. Interferon Cytokine Res. 22:1 (2002), 73–76.
43. [43] Koizumi, J., Kojima, T., Kamekura, R., Kurose, M., Harimaya, A., Murata, M., Osanai, M., Chiba, H., Himi, T., Sawada, N., Changes of gap and tight junctions during differentiation of human nasal epithelial cells using primary human nasal epithelial cells and primary human nasal fibroblast cells in a noncontact coculture system. J. Membr. Biol. 218:1–3 (2007), 1–7.
44. [44] Kurose, M., Kojima, T., Koizumi, J., Kamekura, R., Ninomiya, T., Murata, M., Ichimiya, S., Osanai, M., Chiba, H., Himi, T., Sawada, N., Induction of claudins in passaged hTERT-transfected human nasal epithelial cells with an extended life span. Cell Tissue Res. 330:1 (2007), 63–74.
45. [45] Kamekura, R., Kojima, T., Koizumi, J., Ogasawara, N., Kurose, M., Go, M., Harimaya, A., Murata, M., Tanaka, S., Chiba, H., Himi, T., Sawada, N., Thymic stromal lymphopoietin enhances tight-junction barrier function of human nasal epithelial cells. Cell Tissue Res. 338:2 (2009), 283–293.
46. [46] Obata, K., Kojima, T., Masaki, T., Okabayashi, T., Yokota, S., Hirakawa, S., Nomura, K., Takasawa, A., Murata, M., Tanaka, S., Fuchimoto, J., Fujii, N., Tsutsumi, H., Himi, T., Sawada, N., Curcumin prevents replication of respiratory syncytial virus and the epithelial responses to it in human nasal epithelial cells. PLoS One, 8(9), 2013, e70225.
47. [47] Ogasawara, N., Kojima, T., Go, M., Ohkuni, T., Koizumi, J., Kamekura, R., Masaki, T., Murata, M., Tanaka, S., Fuchimoto, J., Himi, T., Sawada, N., PPARgamma agonists upregulate the barrier function of tight junctions via a PKC pathway in human nasal epithelial cells. Pharmacol. Res. 61:6 (2010), 489–498.
48. [48] Okabayashi, T., Yokota, S., Yoto, Y., Tsutsumi, H., Fujii, N., Fosfomycin suppresses chemokine induction in airway epithelial cells infected with respiratory syncytial virus. Clin. Vaccine Immunol. 16:6 (2009), 859–865.
49. [49] McKimm-Breschkin, J.L., A simplified plaque assay for respiratory syncytial virus–direct visualization of plaques without immunostaining. J. Virol. Methods 120:1 (2004), 113–117.
50. [50] Escalante, C.R., Nistal-Villan, E., Shen, L., Garcia-Sastre, A., Aggarwal, A.K., Structure of IRF-3 bound to the PRDIII-I regulatory element of the human interferon-β enhancer. Mol. Cell 26:5 (2007), 703–716.
51. [51] Schindler, U., Baichwal, V.R., Three NF-κB binding sites in the human E-selectin gene required for maximal tumor necrosis factor α-induced expression. Mol. Cell. Biol. 14:9 (1994), 5820–5831.
52. [52] Yokota, S., Yanagi, H., Yura, T., Kubota, T., Cytosolic chaperonin is up-regulated during cell growth. Preferential expression and binding to tubulin at G1/S transition through early S phase. J. Biol. Chem. 274:52 (1999), 37070–37078.
53. [53] Bentz, G.L., Liu, R., Hahn, A.M., Shackelford, J., Pagano, J.S., Epstein-Barr virus BRLF1 inhibits transcription of IRF3 and IRF7 and suppresses induction of interferon-β. Virology 402:1 (2010), 121–128.
54. [54] Patel, K.B., Xuan, D., Tessier, P.R., Russomanno, J.H., Quintiliani, R., Nightingale, C.H., Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob. Agents Chemother. 40:10 (1996), 2375–2379.
55. [55] Durbin, R.K., Kotenko, S.V., Durbin, J.E., Interferon induction and function at the mucosal surface. Immunol. Rev., 255(1), 2013, 15.
56. [56] Wathelet, M.G., Lin, C.H., Parekh, B.S., Ronco, L.V., Howley, P.M., Maniatis, T., Virus infection induces the assembly of coordinately activated transcription factors on the IFN-beta enhancer in vivo. Mol. Cell, 1(4), 1998, 11.
57. [57] Fitzgerald, K.A., McWhirter, S.M., Faia, K.L., Rowe, D.C., Latz, E., Golenbock, D.T., Coyle, A.J., Liao, S.M., Maniatis, T., IKKε and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 4:5 (2003), 491–496.
58. [58] Yoneyama, M., Suhara, W., Fukuhara, Y., Fukuda, M., Nishida, E., Fujita, T., Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300. EMBO J. 17:4 (1998), 1087–1095.
59. [59] Suhara, W., Yoneyama, M., Kitabayashi, I., Fujita, T., Direct involvement of CREB-binding protein/p300 in sequence-specific DNA binding of virus-activated interferon regulatory factor-3 holocomplex. J. Biol. Chem. 277:25 (2002), 22304–22313.
60. [60] Zhao, W., Qi, J., Wang, L., Zhang, M., Wang, P., Gao, C., LY294002 inhibits TLR3/4-mediated IFN-β production via inhibition of IRF3 activation with a PI3K-independent mechanism. FEBS Lett. 586:6 (2012), 705–710.
61. [61] Yeon, S.H., Song, M.J., Kang, H.R., Lee, J.Y., Phosphatidylinositol-3-kinase and Akt are required for RIG-I-mediated anti-viral signalling through cross-talk with IPS-1. Immunology 144:2 (2015), 312–320.
62. [62] Brandelius, A., Mahmutovic Persson, I., Calven, J., Bjermer, L., Persson, C.G., Andersson, M., Uller, L., Selective inhibition by simvastatin of IRF3 phosphorylation and TSLP production in dsRNA-challenged bronchial epithelial cells from COPD donors. Br. J. Pharmacol. 168:2 (2013), 363–374.
63. [63] Wu, S., Xue, J., Yang, Y., Zhu, H., Chen, F., Wang, J., Lou, G., Liu, Y., Shi, Y., Yu, Y., Xia, C., Hu, Y., Chen, Z., Isoliquiritigenin inhibits interferon-gamma-inducible genes expression in hepatocytes through down-regulating activation of JAK1/STAT1, IRF3/MyD88, ERK/MAPK, JNK/MAPK and PI3K/Akt signaling pathways. Cell. Physiol. Biochem. 37:2 (2015), 501–514.
64. [64] Tumurkhuu, G., Koide, N., Hiwasa, T., Ookoshi, M., Dagvadorj, J., Abu Shadat Mohammod Noman, N., Iftakhar-E-Khuda, I., Naiki, Y., Komatsu, T., Yoshida, T., Yokochi, T., ONO 3403, a synthetic serine protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-{α} and nitric oxide production and protects mice from lethal endotoxic shock. Innate Immun. 17:1 (2011), 97–105.
65. [65] Steel, H.C., Theron, A.J., Cockeran, R., Anderson, R., Feldman, C., Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics. Mediators Inflamm., 2012, 2012, 584262.
66. [66] Yasutomi, M., Ohshima, Y., Omata, N., Yamada, A., Iwasaki, H., Urasaki, Y., Mayumi, M., Erythromycin differentially inhibits lipopolysaccharide- or poly(I:C)-induced but not peptidoglycan-induced activation of human monocyte-derived dendritic cells. J. Immunol. 175:12 (2005), 8069–8076.
67. [67] Gielen, V., Johnston, S.L., Edwards, M.R., Azithromycin induces anti-viral responses in bronchial epithelial cells. Eur. Respir. J. 36:3 (2010), 646–654.
68. [68] Schogler, A., Kopf, B.S., Edwards, M.R., Johnston, S.L., Casaulta, C., Kieninger, E., Jung, A., Moeller, A., Geiser, T., Regamey, N., Alves, M.P., Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells. Eur. Respir. J. 45:2 (2015), 428–439.
69. [69] Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M., Santoro, M.G., Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature 403:6765 (2000), 103–108.
70. [70] Ng, C.T., Mendoza, J.L., Garcia, K.C., Oldstone, M.B., Alpha and beta type 1 interferon signaling: passage for diverse biologic outcomes. Cell 164:3 (2016), 349–352.
71. [71] Teijaro, J.R., Type I interferons in viral control and immune regulation. Curr. Opin. Virol. 16 (2016), 31–40.
72. [72] Iwasaki, A., Medzhitov, R., A new shield for a cytokine storm. Cell 146:6 (2011), 861–862.
73. [73] Teijaro, J.R., Walsh, K.B., Cahalan, S., Fremgen, D.M., Roberts, E., Scott, F., Martinborough, E., Peach, R., Oldstone, M.B., Rosen, H., Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell 146:6 (2011), 980–991.
74. [74] Walsh, K.B., Teijaro, J.R., Wilker, P.R., Jatzek, A., Fremgen, D.M., Das, S.C., Watanabe, T., Hatta, M., Shinya, K., Suresh, M., Kawaoka, Y., Rosen, H., Oldstone, M.B.A., Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus. Proc. Natl. Acad. Sci. U. S. A. 108:29 (2011), 12018–12023.
75. [75] Mallia, P., Message, S.D., Kebadze, T., Parker, H.L., Kon, O.M., Johnston, S.L., An experimental model of rhinovirus induced chronic obstructive pulmonary disease exacerbations: a pilot study. Respir. Res., 7, 2006, 116.
76. [76] Potena, A., Caramori, G., Casolari, P., Contoli, M., Johnston, S.L., Papi, A., Pathophysiology of viral-induced exacerbations of COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2:4 (2007), 477–483.
77. [77] Ivashkiv, L.B., Donlin, L.T., Regulation of type I interferon responses. Nat. Rev. Immunol. 14:1 (2014), 36–49.